The Humira Question: Will the Adalimumab Biosimilars Live Up to the Hype?

Posted by Prateek Yadav on Fri, Dec 07, 2018

Prateek Yadav co-wrote this blog post with Christina Corridon, Tucker Herbert, Didier Chicheportiche and Gustavo Poblete.

The biosimilars market in Europe continues to generate buzz as it captures considerable market share from major blockbuster-branded biologics. Most recently, Celltrion's Truxima, a biosimilar of Roche's MabThera (rituximab), captured 32% market share in 18 European countries. Regulatory agencies have also welcomed biosimilars for the promise of the potential cost savings that they bring. Earlier, the U.K.’s National Health Service reported that switching patients from branded drugs to biosimilars and generics led to a savings of £324 million last year.


>
Read More

Three Takeaways for Impactful Patient Marketing From Digital Pharma East

Posted by Greg Fry on Thu, Nov 01, 2018

As a member of the patient and consumer health team at ZS, I know that patients continue to expect easier access to better content. I was eager to hear how industry leaders were innovating to exceed those heightened expectations at the recent Digital Pharma East conference, which was held Oct. 16-19 in Philadelphia. 


>
Read More

Can the FDA’s Biosimilars Action Plan Change the Game for Biosimilars in the U.S.?

Posted by Tucker Herbert on Wed, Oct 17, 2018

Vartika Pandya and Ross Shahinian co-wrote this blog post with Tucker Herbert.

To address healthcare system costs, the Biologics Price Competition and Innovation Act established an abbreviated pathway for less expensive copies of biologic drugs called biosimilars. Biosimilars have struggled to penetrate the U.S. market, including those developed by major players. Biosimilars of Remicade (infliximab) have managed to capture only 6% of the U.S. market 21 months post-launch. By contrast, the EU has witnessed a more rapid uptake of biosimilars, likely due to stronger payer control and regulatory guidelines facilitating biosimilar penetration (such as the NHS commissioning framework for biological medicines in the U.K.). In the U.S., the FDA has followed suit by developing the Biosimilars Action Plan (BAP) to strike a balance between innovation and competition in the U.S. biologics market.


>
Read More

What Does a Good Forecasting Platform Look Like?

Posted by Matt Wills on Wed, Oct 03, 2018

This post is the third in a four-part series on how pharmaceutical companies can elevate their forecasting operations. To learn more about next-generation analytics in forecasting, check out Matt’s session at the ZS Impact Summit, held Nov. 6-7 in Chicago.

Advances in data availability and the technology needed to harness that data have led many to ask how new technology could be used to implement advanced forecasting platforms for regional or global use. These platforms are typically software that sits online to enhance a forecasting process, whether specific to a country or used globally. Often, these questions are focused on increasing the efficiency of the existing forecasting team. While increasing the efficiency is important, it typically doesn’t generate enough organizational impact relative to the investment required to build and maintain a sophisticated piece of software. Platforms should strive to enable better decisions faster and more broadly than just reducing forecaster effort.


>
Read More

Walking the Walk: How Pharma Companies Can Deliver Patient-Centric Experiences

Posted by Hensley Evans on Thu, Jul 12, 2018

The pharmaceutical industry has been talking about patient centricity for a long time, but despite having been a topic of great interest for more than a decade, there remains a lot of uncertainty about what being a truly patient-centric organization means. What does it mean to walk the walk and, more importantly, how can organizations ensure that a focus on patient centricity not only benefits patients but also drives business success?


>
Read More